NCT07131501View on ClinicalTrials.gov

A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 11, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

August 31, 2029

Conditions
Hepatocellular CarcinomaImmunotherapyPreoperativePD-1CTLA-4
Interventions
PROCEDURE

Radical surgery

Radical surgery

PROCEDURE

TACE treatment

TACE treatment (cTACE, Idarubicin): Preoperative: 1 session; Postoperative: 1 session.

DRUG

Iparomlimab and Tuvonralimab Injection (QL1706)

Iparomlimab and Tuvonralimab Injection (QL1706): 7.5 mg/kg, intravenous infusion, Day 1 of each cycle, Q3W. Neoadjuvant: 2 cycles; Adjuvant: up to 17 cycles.

DRUG

Lenvatinib

Lenvatinib: 8mg (body weight \<60kg) or 12mg (body weight ≥60kg), orally (PO), once daily (QD), Q3W. Consistent daily timing. Neoadjuvant: 2 cycles.

Trial Locations (1)

210029

The First Affiliated Hospital with Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER

NCT07131501 - A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter